Humacyte, Inc. (NASDAQ:HUMA) CEO Sells $1,792,772.30 in Stock

Humacyte, Inc. (NASDAQ:HUMA) CEO Laura E. Niklason sold 277,090 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the transaction, the chief executive officer now owns 4,029,374 shares of the company’s stock, valued at approximately $26,070,049.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Humacyte Price Performance

HUMA opened at $6.05 on Friday. The firm has a 50-day moving average price of $6.86 and a 200-day moving average price of $5.45. Humacyte, Inc. has a twelve month low of $1.96 and a twelve month high of $9.97. The company has a quick ratio of 8.37, a current ratio of 8.37 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $720.46 million, a price-to-earnings ratio of -6.05 and a beta of 1.52.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in shares of Humacyte during the first quarter worth $197,000. Private Advisor Group LLC grew its position in shares of Humacyte by 232.7% in the first quarter. Private Advisor Group LLC now owns 317,624 shares of the company’s stock valued at $988,000 after purchasing an additional 222,144 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Humacyte by 28.7% during the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after purchasing an additional 896,415 shares during the period. Victory Capital Management Inc. purchased a new stake in Humacyte during the 4th quarter worth about $29,000. Finally, Capstone Investment Advisors LLC purchased a new stake in Humacyte during the 1st quarter worth about $972,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on HUMA shares. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 target price on shares of Humacyte in a research report on Tuesday, July 2nd. BTIG Research increased their price objective on Humacyte from $8.00 to $11.00 and gave the company a “buy” rating in a report on Monday, July 15th. Finally, Benchmark reissued a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research report on Monday, August 12th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Humacyte has a consensus rating of “Moderate Buy” and an average target price of $8.60.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.